in Belgium, scientists from VIB-UNIVERSITY of antwerp and the KU Leuven, with a ATP10B a new risicogen were identified in the Parkinson’s disease-what is it to be an interesting therapeutic target for this disease. “We have initiated the search for methods of the production of the gene is able to influence,” according to a joint statement.
At the Center for Molecular Neuroscience (VIB-UNIVERSITY of antwerp), two of the mutations in this gene may be detected in children at a very young age with Parkinson’s disease are suffering when their parents were healthy. These changes have resulted in a loss of ATP10B protein, and function.
In the Laboratory of Cellular Transport Systems, KU Leuven, belgium), it was shown that this gene allows for the transport of a lipid that plays a central role in Parkinson’s disease, and that this function is disrupted by mutations. The reduced amount of ATP10B also led to the neuronaal the loss of what neurons are more sensitive for the environmental factors that are the risk of the disease increases.
“These new findings make ATP10B be an interesting therapeutic target for Parkinson’s disease worldwide, more than 10 million people in this country, of which 2 million are in Europe. Currently, however, there is still no effective therapy. For a better understanding of the key proteins and pathways involved in the onset and course of the disease, and Parkinson’s disease, it is necessary to have a course of treatment to be able to develop, which is the cause of approach,” according to the statement. The pharmaceutical companies have already shown interest in the search for methods for the production of a gene to affect you.
